Navigation Links
Pharmaceutical Budget and Staffing: Powerful New Metrics-Based Study
Date:2/7/2008

CHAPEL HILL, N.C., Feb. 7 /PRNewswire/ -- Falling stock prices, devaluing dollar, soaring gas prices, and the slumping real estate market are just a few of the symptoms of the recession hitting the U.S. economy. While a recession will impact all industries, it may have a deeper impact on pharma and biotech companies as they have already been dealing with increasing pricing and regulatory pressures and decreasing numbers of newly approved therapies. Given the current environment, it is imperative for companies to maintain the appropriate mix of budgets and staffing to meet corporate objectives.

The current report, U.S. Pharmaceutical Budget and Staffing Excellence: Benchmarking the Resources Required to Drive Productivity and Growth, can be an invaluable resource allowing pharmaceutical and biotech executives to critically assess key business functions and resources against thirty-six top pharma and biotech companies. The rich metrics contained in this comprehensive report emanate from survey responses from staffing executives at such elite pharmaceutical and biotech companies as Abbott Labs, AstraZeneca, Bristol-Myers Squibb, J&J, Eli Lilly GlaxoSmithKline, Merck, Novartis, Pfizer, Roche and Sanofi-Aventis.

Executive insight across seven critical functional areas, including:

* Marketing Operations

* Marketing Services

* Sales Support

* Managed Care

* State & Government Affairs

* Finance

* Legal and Compliance

Sampling of the key findings harnessed from the report include:

* Marketing Services groups support an average of 7.8 brands with 6.7 FTEs

allocated per brand promoted

* Sales Support groups allocate approximately $460,000, including labor,

overhead and outsourcing, per sales support FTE

* Managed Care groups report an average of 18 FTEs allocated to Customer

Marketing Strategy

* Finance budgets as a percentage of sales average 1.33%


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 19, 2014 The Asian Automatic patient ... with analysis and forecast of revenue. The Automatic patient ... around $463.9 million by 2018, at a developing CAGR ... the TOC of the Asian Automatic patient billing market, ... This also provides a glimpse of the segmentation of ...
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, Sugar and ... and Forecast (2011 - 2016)," analyzes the chocolate ... the major market drivers, restraints, and opportunities for the ... The global chocolate market is expected to grow from ... an estimated CAGR of 2.7% from 2011 to 2016. ...
(Date:10/19/2014)... 2014 The report "Unmanned Ground ... Security), Technology, Payload, Type & by Geography - ... global unmanned ground vehicle market into various sub ... market sizes. The report also identifies the factors ... it along with the adoption trends. , The ...
(Date:10/18/2014)... 19, 2014 The “Human Insulin ... Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, ... NovoRapid, Novomix, Tresiba, Others) - Forecast to 2018” ... restraints, challenges, opportunities, current market trends, and strategies ... the estimates and forecasts of the revenue and ...
Breaking Biology Technology:The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 2Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 5Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5
... Companies in Plant Biotechnology Industry, WILMINGTON, Del., Oct. ... one of the best employers in the biotechnology and,pharmaceutical ... This is the first DuPont appearance on the ... it ahead of other companies in the,plant biotechnology industry. ...
... 18 NPS,Pharmaceuticals, Inc. (Nasdaq: NPSP ) announced ... offer for any and all of its outstanding,3.0% Convertible ... New,York City time, on October 17, 2007. As ... million principal,amount of the notes, representing approximately 99.7% of ...
... -- Company Completes Enrollment in First Cohort --, ... Nventa,Biopharmaceuticals Corporation (TSX:NVN) today announced that the Company,has ... Phase 1 clinical trial,to assess the safety and ... neoplasia (CIN). The trial is expected to ...
Cached Biology Technology:DuPont Named Among Top Biotechnology Employers by Science Magazine 2NPS Pharmaceuticals Announces Results of Tender Offer 2NPS Pharmaceuticals Announces Results of Tender Offer 3Nventa updates progress of cervical dysplasia trial with new HspE7 2Nventa updates progress of cervical dysplasia trial with new HspE7 3Nventa updates progress of cervical dysplasia trial with new HspE7 4Nventa updates progress of cervical dysplasia trial with new HspE7 5
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
(Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
(Date:10/16/2014)... Oregon and Washington land managers have a new synthesis ... eastside moist mixed-conifer (MMC) forests in the two states. ... Forests in Eastern Oregon and Washington: A Synthesis of ... Management, a general technical report published by the U.S. ... response to a request from managers for a synthesis ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... 16, 2008) The overall condition of the nation,s coastal ... environmental assessment. The National Coastal Condition Report III (NCCRIII) ... of U.S. coastal and Great Lakes waters. ... Protection Agency (EPA); the National Oceanic and Atmospheric Administration ...
... Plants, genetically modified to ease the breaking down of their ... greener way of making ethanol, according to researchers who add ... food for livestock. Lignin, a major component of ... plants with the strength to withstand strong gusts of wind ...
... NEW YORK, Dec. 22, 2008 NYU Langone Medical Center ... La Jolla, Calif., have discovered an unexpected cause for the ... of the central nervous system, according to a study published ... new way of thinking about how the human immune system ...
Cached Biology News:Modified plants may yield more biofuel 2Peering inside the skull of a mouse to solve meningitis mystery 2Peering inside the skull of a mouse to solve meningitis mystery 3
NovaScreen offers cell biology, cell culture and molecular biology services for companies who lack a cell culture facility....
... Service The Human Genetic Cell Bank ... (EBV) immortalisation of human peripheral blood lymphocytes ... cell lines (LCLs). These cell lines are ... source of genomic DNA and RNA. ...
... The Panorama Mouse/Rat Tissue Extract Protein Array ... in various tissue extracts. The expression of ... using a protein specific antibody. When the ... visualized by a sensitive chemiluminescent or fluorescent ...
Glycerol-based mounting medium for immunofluorescence microscopy. Formulated to retard photobleaching of fluorochromes such as fluorescein and rhodamine. Product can also be used as a diluent for fl...
Biology Products: